Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Antimicrobial activity of prulifloxacin in comparison with other fluoroquinolones against community-acquired urinary and respiratory pathogens isolated in Greece.

Karageorgopoulos DE, Maraki S, Vatopoulos AC, Samonis G, Schito GC, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1417-22. doi: 10.1007/s10096-013-1891-z. Epub 2013 May 19.

PMID:
23686506
2.

DNA bacterial load in children with bacteremic pneumococcal community-acquired pneumonia.

Esposito S, Marchese A, Tozzi AE, Rossi GA, Da Dalt L, Bona G, Pelucchi C, Schito GC; Italian Pneumococcal CAP group, Principi N.

Eur J Clin Microbiol Infect Dis. 2013 Jul;32(7):877-81. doi: 10.1007/s10096-013-1821-0. Epub 2013 Jan 25.

PMID:
23354677
3.

Bacteremic pneumococcal community-acquired pneumonia in children less than 5 years of age in Italy.

Esposito S, Marchese A, Tozzi AE, Rossi GA, Da Dalt L, Bona G, Pelucchi C, Schito GC, Principi N; Italian Pneumococcal CAP Group.

Pediatr Infect Dis J. 2012 Jul;31(7):705-10. doi: 10.1097/INF.0b013e31825384ae.

PMID:
22426300
4.

Detection of Streptococcus pneumoniae and identification of pneumococcal serotypes by real-time polymerase chain reaction using blood samples from Italian children ≤ 5 years of age with community-acquired pneumonia.

Marchese A, Esposito S, Coppo E, Rossi GA, Tozzi A, Romano M, Da Dalt L, Schito GC, Principi N.

Microb Drug Resist. 2011 Sep;17(3):419-24. doi: 10.1089/mdr.2011.0031. Epub 2011 Apr 21.

PMID:
21510746
5.

Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis?

Schito GC, Gualco L, Naber KG, Botto H, Palou J, Mazzei T, Marchese A.

J Chemother. 2010 Oct;22(5):345-54.

PMID:
21123159
6.

The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.

Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A.

Int J Antimicrob Agents. 2009 Nov;34(5):407-13. doi: 10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7.

PMID:
19505803
7.

Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy.

Stefani S, Mezzatesta ML, Fadda G, Mattina R, Palù G, Rossano F, Tufano MA, Schito GC, Nicoletti G.

J Chemother. 2008 Oct;20(5):561-9.

PMID:
19028617
8.

European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis.

Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A.

J Clin Microbiol. 2008 Aug;46(8):2605-12. doi: 10.1128/JCM.00640-08. Epub 2008 Jun 25.

9.

[Recent results of multinational studies on antibiotic resistance: should we have "PROTECTion" against these resistances?].

Marchese A, Schito GC.

Med Mal Infect. 2007 Nov;37 Spec No 1:2-5. French. No abstract available.

PMID:
18376502
10.

Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules.

Concia E, Novelli A, Schito GC, Marchese A.

J Chemother. 2007 Dec;19(6):609-19. Review.

PMID:
18230541
11.

Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp.

Roveta S, Marchese A, Schito GC.

Int J Antimicrob Agents. 2008 Apr;31(4):321-8. doi: 10.1016/j.ijantimicag.2007.11.012. Epub 2008 Feb 21.

PMID:
18201873
12.
13.

Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.

Roveta S, Schito AM, Marchese A, Schito GC.

Int J Antimicrob Agents. 2007 Nov;30(5):415-21. Epub 2007 Sep 4.

PMID:
17768034
14.

In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.

Gualco L, Schito AM, Schito GC, Marchese A.

Int J Antimicrob Agents. 2007 Jun;29(6):679-87. Epub 2007 Mar 23.

PMID:
17363225
15.

Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice.

Galatti L, Mazzaglia G, Greco A, Sessa E, Cricelli C, Schito GC, Nicoletti G, Spina E, Caputi AP.

Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):422-8.

PMID:
17323404
16.

Recent findings from multinational resistance surveys: are we 'PROTEKTed' from resistance?

Marchese A, Schito GC.

Int J Antimicrob Agents. 2007 Feb;29 Suppl 1:S2-5.

PMID:
17307653
18.

The importance of the development of antibiotic resistance in Staphylococcus aureus.

Schito GC.

Clin Microbiol Infect. 2006 Mar;12 Suppl 1:3-8. Review.

19.

Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study.

Galatti L, Sessa A, Mazzaglia G, Pecchioli S, Rossi A, Cricelli C, Schito GC, Nicoletti G, Caputi AP.

J Antimicrob Chemother. 2006 Mar;57(3):551-6. Epub 2006 Jan 25.

PMID:
16436541
20.

Predicting the clinical efficacy of generic formulations of ceftriaxone.

Schito GC, Keenan MH.

J Chemother. 2005 Sep;17 Suppl 2:33-40.

PMID:
16315582
21.

Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).

Schito GC, Felmingham D.

Int J Antimicrob Agents. 2005 Dec;26(6):479-85. Epub 2005 Nov 9.

PMID:
16289710
22.

Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.

Roveta S, Schito AM, Marchese A, Schito GC.

Int J Antimicrob Agents. 2005 Nov;26(5):366-72. Epub 2005 Oct 7.

PMID:
16216467
24.

Antibiotic susceptibility and serotype distribution in Streptococcus pneumoniae circulating in Italy: results of the SEMPRE surveillance study (2000-2002).

Marchese A, Gualco L, Cochetti I, Montanari MP, Speciale AM, Musumeci SR, Varaldo PE, Nicoletti G, Schito GC.

Int J Antimicrob Agents. 2005 Aug;26(2):138-45.

PMID:
16024234
25.

The Sentinel Project: an update on the prevalence of antimicrobial resistance in community-acquired respiratory Streptococcus pneumoniae and Haemophilus spp. in Italy.

Marchese A, Ardito F, Fadda G, Fontana R, Lo Cascio G, Nicoletti G, Speciale AM, Schito GC.

Int J Antimicrob Agents. 2005 Jul;26(1):8-12.

PMID:
15967638
26.

Resistance trends in Streptococcus pneumoniae (PROTEKT years 1-3 [1999-2002]).

Schito GC.

J Chemother. 2004 Dec;16 Suppl 6:19-33. Review. No abstract available.

PMID:
15690683
27.

In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.

Testore GP, Dori L, Buonomini AR, Schito GC, Soro O, Fortina G, Andreoni S, Carlone N, Tullio V, Andreoni M.

Diagn Microbiol Infect Dis. 2004 Nov;50(3):187-92.

PMID:
15541604
28.

Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections.

Blandino G, Marchese A, Ardito F, Fadda G, Fontana R, Lo Cascio G, Marchetti F, Schito GC, Nicoletti G.

Int J Antimicrob Agents. 2004 Nov;24(5):515-8.

PMID:
15519488
29.

In vitro activity of ertapenem against selected respiratory pathogens.

Marchese A, Gualco L, Schito AM, Debbia EA, Schito GC.

J Antimicrob Chemother. 2004 Nov;54(5):944-51. Epub 2004 Oct 7.

PMID:
15472001
30.

Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.

Schito AM, Schito GC.

J Chemother. 2004 Apr;16 Suppl 2:3-7. Review. No abstract available.

PMID:
15255554
31.

Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.

Schito GC, Marchese A, Elkharrat D, Farrell DJ; PROTEKT Study Group.

J Chemother. 2004 Feb;16(1):13-22.

PMID:
15077994
32.

Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms.

Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC, Schito AM.

Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:95-100.

PMID:
14527779
33.

Why fosfomycin trometamol as first line therapy for uncomplicated UTI?

Schito GC.

Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:79-83. Review.

PMID:
14527776
34.

In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.

Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM.

Int J Antimicrob Agents. 2003 Oct;22 Suppl 2:53-9.

PMID:
14527772
35.

Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000.

Schito AM, Schito GC, Debbia E, Russo G, Liñares J, Cercenado E, Bouza E.

J Chemother. 2003 Jun;15(3):226-34.

PMID:
12868547
37.

A human placental polydeoxyribonucleotide (PDRN) may promote the growth of human corneal fibroblasts and iris pigment epithelial cells in primary culture.

Muratore O, Cattarini G, Gianoglio S, Tonoli EL, Saccà SC, Ghiglione D, Venzano D, Ciurlo C, Lantieri PB, Schito GC.

New Microbiol. 2003 Jan;26(1):13-26.

PMID:
12578307
38.

Is antimicrobial resistance also subject to globalization?

Schito GC.

Clin Microbiol Infect. 2002;8 Suppl 3:1-8; discussion 33-5. Review.

39.

Postantibiotic effect and delay of regrowth in strains carrying mutations that save proteins or RNA.

Dolcino M, Zoratti A, Debbia EA, Schito GC, Marchese A.

Antimicrob Agents Chemother. 2002 Dec;46(12):4022-5.

40.

An investigation of the etiology of community-acquired lower respiratory tract infections (LRTI) and resistance to antibiotics in Italy (the EOLO Study).

Sanguinetti CM, Donner CF, De Benedetto F, Nicoletti G, Scatigna M, Schito GC.

Monaldi Arch Chest Dis. 2002 Apr;57(2):105-6. No abstract available.

PMID:
12357835
41.

Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries.

Schito GC, Georgopoulos A, Prieto J.

J Antimicrob Chemother. 2002 Jul;50 Suppl:7-11.

PMID:
12077154
42.

Nasopharyngeal carriage of Streptococcus pneumoniae in healthy children: implications for the use of heptavalent pneumococcal conjugate vaccine.

Marchisio P, Esposito S, Schito GC, Marchese A, Cavagna R, Principi N; Hercules Project Collaborative Group.

Emerg Infect Dis. 2002 May;8(5):479-84.

43.

Microbial epidemiology patterns of surgical infection pathogens.

Debbia EA, Schito GC, Gualco L, Tonoli E, Dolcino M, Marchese A.

J Chemother. 2001 Nov;13 Spec No 1(1):84-8. Review.

PMID:
11936386
44.

Epidemiology of major respiratory pathogens.

Debbia EA, Schito GC, Zoratti A, Gualco L, Tonoli E, Marchese A.

J Chemother. 2001 Nov;13 Spec No 1(1):205-10. Review.

PMID:
11936367
45.

The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens.

Goldstein F, Bryskier A, Appelbaum PC, Bauernfeind A, Jacobs M, Schito GC, Wise R.

Clin Microbiol Infect. 1998 Apr;4 Suppl 2:S8-S18. No abstract available.

46.
47.

In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy.

Marchese A, Debbia EA, Schito GC.

Clin Microbiol Infect. 1999 Aug;5(8):488-495.

48.

Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens.

Marchese A, Debbia EA, Bryskier A, Schito GC.

Clin Microbiol Infect. 1999 May;5(5):282-287. No abstract available.

49.

European survey of glycopeptide susceptibility in Staphylococcus spp.

Schito GC, Auckenthaler R, Marchese A, Bauernfeind A.

Clin Microbiol Infect. 1999 Sep;5(9):547-553.

50.

Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests.

Livermore DM, Struelens M, Amorim J, Baquero F, Bille J, Canton R, Henning S, Gatermann S, Marchese A, Mittermayer H, Nonhoff C, Oakton KJ, Praplan F, Ramos H, Schito GC, Van Eldere J, Verhaegen J, Verhoef J, Visser MR.

J Antimicrob Chemother. 2002 Feb;49(2):289-300.

PMID:
11815570

Supplemental Content

Loading ...
Support Center